These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36017748)

  • 1. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
    Muniesa C; Gallardo F; García-Doval I; Estrach MT; Combalia A; Morillo-Andújar M; De la Cruz-Vicente F; Machan S; Moya-Martínez C; Rovira R; Sanchez-Gonzalez B; Acebo E; Amutio E; Peñate Y; Losada-Castillo MDC; García-Muret MP; Iznardo H; Román-Curto C; Cañueto J; Fernández-de-Misa R; Flórez Á; Izu RM; Torres-Navarro I; Zayas A; Pérez-Paredes G; Blanes M; Yanguas JI; Pérez-Ferriols A; Callejas-Charavia M; Ortiz-Romero PL; Pérez-Gil A; Prieto-Torres L; González-Barca E; Servitje O
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):57-64. PubMed ID: 36017748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.
    Hirai Y; Sakurai J; Yoshida S; Kikuchi T; Mitsuhashi T; Miyake T; Fujimura T; Abe R; Fujikawa H; Boki H; Suga H; Shibata S; Miyagaki T; Shimauchi T; Kiyohara E; Kawakami Y; Morizane S
    J Dermatol; 2024 Aug; 51(8):1037-1049. PubMed ID: 38874430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
    Barta SK; Liu N; DerSarkissian M; Chang R; Ye M; Duh MS; Surinach A; Fanale M; Yu KS
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e21-e32.e4. PubMed ID: 37919137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
    Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
    Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin in CD30
    Enos TH; Feigenbaum LS; Wickless HW
    Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides.
    Kelly KA; Edenfield L; Seegars MB; Vaidya R; Feldman SR; Strowd LC
    J Drugs Dermatol; 2023 Dec; 22(12):e33-e34. PubMed ID: 38051830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
    Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
    J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
    Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
    Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
    Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
    JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity.
    Papadavid E; Kapniari E; Pappa V; Nikolaou V; Iliakis T; Dalamaga M; Jonak C; Porkert S; Engelina S; Quaglino P; Ortiz-Romero PL; Vico C; Cozzio A; Dimitriou F; Guiron R; Guenova E; Hodak E; Bagot M; Scarisbrick J
    Br J Dermatol; 2021 Nov; 185(5):1035-1044. PubMed ID: 34137025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
    Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
    JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.
    Corbin ZA; Nguyen-Lin A; Li S; Rahbar Z; Tavallaee M; Vogel H; Salva KA; Wood GS; Kim YH; Nagpal S
    J Neurooncol; 2017 May; 132(3):439-446. PubMed ID: 28271282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
    Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.
    Kim SJ; Do YR; Lee HS; Lee WS; Kong JH; Kwak JY; Eom HS; Moon JH; Yi JH; Lee JO; Jo JC; Yang DH
    Blood Res; 2023 Dec; 58(4):194-200. PubMed ID: 38031473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
    Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS
    Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of mycosis fungoide : focus on brentuximab vedotin].
    Lebas E; Collins P; Bonnet C; Libon F; Dezfoulian B; Nikkels AF
    Rev Med Liege; 2021 Apr; 76(4):224-231. PubMed ID: 33830684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
    Nguyen GH; Olson LC; Magro CM
    Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.